April 2025
1. ALMEIDA BA, Paixao ES, Pitta ML, Barreto ML, et al
   Missed opportunities for equity: a crucial perspective on the Lancet's Zika virus research Series.
   Lancet Infect Dis. 2025 Apr 3:S1473-3099(25)00226.
   

   >> Share

   
   February 2025
2. LACKRITZ EM, Ng LC, Marques ETA, Rabe IB, et al
   Zika virus: advancing a priority research agenda for preparedness and response.
   Lancet Infect Dis. 2025 Feb 27:S1473-3099(24)00794.
   

   >> Share

   
   
3. OSTROWSKY JT, Katzelnick LC, Bourne N, Barrett ADT, et al
   Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development.
   Lancet Infect Dis. 2025 Feb 27:S1473-3099(24)00750.
   

   >> Share

   
   
4. ABAD-FRANCH F, Carvajal-Cortes JJ, Rabelo ACL, Gusmao EVV, et al
   Mosquito-disseminated pyriproxyfen for mosquito-borne disease control in Belo Horizonte, Brazil: a pragmatic, before-after control-intervention paired-series trial.
   Lancet Infect Dis. 2025;25:176-187.
   

   >> Share

   
   January 2025
5. KIRBY T
   Ana Bispo-from polio to Zika virus and beyond.
   Lancet Infect Dis. 2025;25:21.
   

   >> Share

   
   September 2024
6. BRICKLEY EB, Miranda-Filho DB, Ximenes RAA
   Preparing for the rapid research response to the possible vertical transmission of Oropouche virus: lessons from a decade of congenital Zika research.
   Lancet Infect Dis. 2024 Sep 27:S1473-3099(24)00618.
   

   >> Share

   
   January 2024
7. SALJE H
   Achieving zero deaths from dengue virus under evolving population immunity.
   Lancet Infect Dis. 2024;24:12-13.
   

   >> Share

   
   June 2023
8. LOW JG, Ooi EE
   Inactivated Zika virus vaccine and the complexity of flavivirus antigenicity.
   Lancet Infect Dis. 2023 Jun 27:S1473-3099(23)00202.
   

   >> Share

   
   
9. KOREN MA, Lin L, Eckels KH, De La Barrera R, et al
   Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.
   Lancet Infect Dis. 2023 Jun 27:S1473-3099(23)00192.
   

   >> Share

   
   January 2023
10. WILDER-SMITH A, Durbin A
    Promising efforts to develop an mRNA vaccine against Zika.
    Lancet Infect Dis. 2023 Jan 19:S1473-3099(22)00827.
    

    >> Share

    
    
11. ESSINK B, Chu L, Seger W, Barranco E, et al
    The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.
    Lancet Infect Dis. 2023 Jan 19:S1473-3099(22)00764.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share